BIOMAT Database Logo BIOMAT Database Logo

Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. 2015

Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Department of Oncology, University of Torino, Turin, Italy.

Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes endowed with potent MHC-independent antitumor activity. CIK cells are emerging as promising therapeutic approach in the field of cancer adoptive immunotherapy, with biologic features favoring their transferability into clinical applications. Aim of this review is to present the biologic characteristic of CIK cells, discussing the main preclinical findings and initial clinical applications in the field of solid tumors.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell
D055612 Cytokine-Induced Killer Cells Mononuclear leukocytes that have been expanded in CELL CULTURE and activated with CYTOKINES such as INTERLEUKIN-2 to produce large numbers of highly cytotoxic cells. CIK Cells,Lymphocyte-Activated Killer Cell,Lymphocyte-Activated Killer Cells,CIK Cell,Cell, Lymphocyte-Activated Killer,Cells, Lymphocyte-Activated Killer,Cytokine Induced Killer Cells,Cytokine-Induced Killer Cell,Killer Cell, Cytokine-Induced,Killer Cell, Lymphocyte-Activated,Killer Cells, Cytokine-Induced,Killer Cells, Lymphocyte-Activated,Lymphocyte Activated Killer Cell,Lymphocyte Activated Killer Cells
D055655 NK Cell Lectin-Like Receptor Subfamily K An activating NK cell lectin-like receptor subfamily that regulates immune responses to INFECTION and NEOPLASMS. Members of this subfamily generally occur as homodimers. CD314 Antigen,Killer Cell Lectin-Like Receptor Subfamily K,Killer Cell Lectin-Like Receptor Subfamily K, Member 1,NK Cell Lectin-Like Receptor Subfamily K, Member 1,NK Cell Receptor D,NKG2-D Receptor,NKG2D Receptor,Antigen, CD314,Killer Cell Lectin Like Receptor Subfamily K,Killer Cell Lectin Like Receptor Subfamily K, Member 1,NK Cell Lectin Like Receptor Subfamily K,NK Cell Lectin Like Receptor Subfamily K, Member 1,NKG2 D Receptor,Receptor, NKG2-D,Receptor, NKG2D

Related Publications

Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Cytokine induced killer cells as promising immunotherapy for solid tumors.
January 2011, Journal of Cancer,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells.
July 2014, Expert opinion on biological therapy,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.
January 2017, Frontiers in immunology,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Promising immunotherapy: Highlighting cytokine-induced killer cells.
June 2019, Journal of cellular biochemistry,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Cancer Immunotherapy with Cytokine-Induced Killer Cells.
June 2017, Targeted oncology,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Current immunotherapy for solid tumors.
May 2009, Immunotherapy,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis.
April 2021, Medicine,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Cytokine-induced memory-like natural killer cells for cancer immunotherapy.
December 2021, Stem cell research & therapy,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia.
February 2015, Oncology letters,
Lidia Giraudo, and Loretta Gammaitoni, and Michela Cangemi, and Ramona Rotolo, and Massimo Aglietta, and Dario Sangiolo
Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial.
September 2009, Hematological oncology,
Copied contents to your clipboard!